Details of the Drug

General Information of Drug (ID: DMOB3CI)

Drug Name

ALXN1720

Synonyms

gefurulimab

Indication

Disease Entry	ICD 11	Status	REF
Generalized myasthenia gravis	8C60	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Monoclonal antibody

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Generalized myasthenia gravis

ICD Disease Classification

8C60

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Complement C5 (CO5)	DTT	C5	7.69E-01	-0.12	-0.23

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05556096) A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis. U.S.National Institutes of Health.
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight